Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease

Journal of Nuclear Medicine

Volumn 38, Issue 1, 1997, Pages 1-6

  Asenbaum, Susanne ^a   Brücke, Thomas ^a   Pirker, Walter ^a   Podreka, Ivo ^a   Angelberger, Peter ^a   Wenger, Sylvia ^a   Wöber, Christian ^a   Müller, Christian ^a   Deecke, Lüder ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

iodine 123 CIT; Parkinson's disease; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123;

ADULT; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HUMAN; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; RECEPTORS, PRESYNAPTIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 1842327493     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Brücke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991;11:220-228.
2. Neumeyer JL, Wang S, Milius RA, et al. Iodine-123-2β-carboxymethoxy-3β-(4-iodophenyl)tropane (β-CIT): high affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991;34:3144-3146.
3. 123I]β-CIT. Eur J Pharmacol 1991;200:369-370.
4. Shaya EK, Scheffel U, Dannals RF, et al. In vivo imaging of dopamine reuptake sites in the primate brain using SPECT and iodine-123-labeled RTI-55. Synapse 1992;10: 169-172.
5. Boja JW, Patel A, Carroll FI, et al. Iodine-123-RTI-55: a potent ligand for dopamine transporters. Eur J Pharmacol 1991;194:133-134.
6. Scheffel U, Dannals RF, Cline EJ, et al. Iodine-123-RTI-55, an in vivo label for serotonin transporters. Synapse 1992;11:134-139.
7. 123I]β-CIT: pharmacological characterization of brain uptake in non-human primates. Synapse 1993;13:295-309.
8. Müller L, Halldin C, Farde L, et al. Carbon-11-β-CIT, a cocaine analog. Preparation, autoradiography and preliminary PET investigations. Nucl Med Biol 1993;20:249-255.
9. Pirker W, Asenbaum S, Kasper S, et al. β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm 1995;100:247-256.
10. Kaufmann MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991;49:43-49.
11. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991;56:192-198.
12. Kuikka JT, Bergström KA, Vanninen E, Laulumaa V, Hartikainen P, Länsimies E. Initial experience with single-photon emission tomography using iodine-123-labeled 2β-carbomethoxy-3β-(4-iodophenyl)tropane in human brain. Eur J Nucl Med 1993; 20:783-786.
13. 123I]β-CIT. Binding kinetics in the human brain. J Neural Transm 1993;94:137-146.
14. Innis RB, Seibyl JP, Scanley BE, et al. Single-photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
15. Brücke T, Asenbaum S, Angelberger P, et al. Iodine-123-β-CIT binding in the human brain: SPECT studies in parkinsonian patients and normal controls. Soc Neurosci Abstr 1994;20(part 2):1464.
16. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
17. 123I]β-CIT SPECT. Parkinsonism and Related Disorders 1995;1:47-51.
18. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;6:253-259.
19. Fahn S, Elton RL, Members of the Unified Parkinson's Disease Rating Scale Development Commitee Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, vol. 2. Florham Park, NY: Macmillan Healthcare Information; 1987:153-164.
20. 3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry 1988;24:299-309.
21. Palacios JM, Camps M, Cortes R, Probst A. Mapping dopamine receptors in the human brain. J Neural Transm 1988;27(suppl 27):227-235.
22. De Keyser J, DeBacker J-P, Ebinger G, Vauquelin G. Hydrogen-3-GBR-12935 binding to dopamine uptake sites in the human brain. J Neurochem 1989;53:1400-1404.
23. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
24. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
25. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease, studied with PET. Brain 1990;113:1539-1552.
26. 18F-Dopa uptake: difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 1991;54:898-904.
27. 3H]-2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol Pharmacol 1989;36:518-524.
28. 11C]WIN 35,428). J Lab Compd Radiopharm 1993;33:147-152.
29. Zednik N, Angel I, Paul SM, Kleinmann JE. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol 1986;126:175-176.
30. De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol 1990;27:157-161.
31. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994;36:237-239.
32. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175-1181.
33. Janowsky A, Vocci F, Berger P, et al. Hydrogen-3-GBR 12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. J Neurochem 1987;49:617-621.
34. Maloteaux J-M, Vanisberg M-A, Laterre C, et al. Hydrogen-3-GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur J Pharmacol 1988;156:331-340.
35. 3H]-cocaine binding to the dopamine transporter in Parkinson's disease. Eur J Pharmacol 1983;95:145-146.
36. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
37. German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989;26:507-514.
38. Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol 1989;26: 766-770.
39. Rinne JO, Rummukainen J, Paljärvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47-50.
40. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20: 415-455.
41. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986;45:19-34.
42. Kish SJ, Shannar K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiological and clinical implications. N Engl J Med 1988;318:876-880.
43. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
44. 11C]nomifensine uptake using positron emission tomography. J Cereb Blood Flow Metab 1990;10:307-316.
45. Brücke T, Asenbaum S, Pozzera A, et al. Dopaminergic nerve cell loss in Parkinson's disease quantified with [I-123]-β-CIT and SPECT correlates with clinical findings. Mov Disord 1994;9(suppl 1):120.
46. Garnett ES, Nahmias C, Firnau G. Central dopaminergic pathways in hemiparkmsonism examined by positron emission tomography. Can J Neurol Sci 1984;11:174-179.
47. Karbe H, Holthoff V, Huber M, et al. Positron emission tomography in degenerative disorders of the dopaminergic system. J Neural Transm 1992;4:121-130.
48. Marek KL, Seibyl JP, Zoghbi S, et al Iodine-123-β-CIT, SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-2.17.
49. Kempster PA, Gibb WRG, Stern GM, Lees AJ. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry 1989;52:72-76.
50. Heinonen EH, Anttila MI, Lammintausta RAS. Pharmacokinetics and clinical pharmacology of selegilin. In: Szelenyi, ed. Inhibitors of monoamine oxidase B. Pharmacology and clinical use in neurodegenerative disorders. Basel: Birkhäuser; 1993:201-213.
51. Xu C, Coffey LL, Reith ME. Translocation of dopamine and binding of 2-beta-carbomethoxy-3-beta-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. J Biochem Pharmacol 1995;49:339-350.